| |
Sept. 25 - 26, 2024 | San Diego, CA Learn out of the box strategies for MSLs to engage with KOLs and HCPs post-pandemic, successful approaches to establishing medical communications plans ahead of a launch. Complimentry Passes Available! Learn More. .png)
|
|
Today’s Big NewsAug 6, 2024 |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
| By Nick Paul Taylor Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by incorporating the lead candidate into a co-development deal with Daiichi Sankyo. |
|
|
|
By James Waldron After BioMarin conducted a spring clean of its pipeline in April, the company has decided that it also needs to offload a preclinical gene therapy for a condition that causes heart muscles to thicken. |
By Gabrielle Masson After Biogen and Novartis walked away from partnerships with Sangamo Therapeutics in 2023, the biotech has secured a pact with Roche’s Genentech working on intravenous genomic medicines for neurodegenerative diseases. |
By Nick Paul Taylor Ultimovacs’ cancer vaccine UV1 has failed yet another midphase clinical trial. The third flop, this time in head and neck cancer, leaves UV1 with one shot at salvation before the Norwegian biotech reaches the end of its cash runway. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By James Waldron Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets. |
By James Waldron Levicept arose from the metaphorical ashes of Pfizer’s former R&D campus in the U.K. Now, the biotech has scored a phase 2 win for an osteoarthritis drug that can also be traced back to the Big Pharma. |
By Gabrielle Masson A new global life science credit firm, dubbed Symbiotic Capital, has raised more than $600 million. The organization will deliver credit solutions to companies across biotech, medtech, synthetic biology and other healthcare sectors. |
By Kevin Dunleavy The family of a Baltimore woman whose cells were extracted for medical research without her consent more than 70 years ago has filed another lawsuit against drugmakers that allegedly profited from the discoveries they made using her genetic material. The estate has sued Novartis and Viatris, seeking a jury trial and the “full amount” of profits obtained through their use of the “stolen” cells. |
By Annalee Armstrong Asset manager TPG, which has supported biotechs such as Sionna Therapeutics and Santa Ana Bio, has topped up its Life Science Innovations fund, bringing total capital raised for the effort to $580 million. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Darren Incorvaia Three years since founding Site Alliance in 2021, Genentech is now sharing data showing sites in the alliance enroll more Black and Hispanic/Latinx patients than other sites in the same studies and enroll these underrepresented groups about two times faster. |
By Heather Landi Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos, to CVC Capital Partners for $925 million. |
By Kevin Dunleavy Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year. That number includes the 1,500 staffers the company said it laid off in the first quarter. |
By Heather Landi Hims & Hers launched a virtual weight management program in December, adding compounded GLP-1 medications in May, and that investment is quickly paying off. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
|
Thursday, September 5, 2024 | 12pm ET / 9am PT Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. However, it still faces key challenges. Join us to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca that are aimed at addressing disparities in cancer care. Register now. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
